Overview of the pathogenesis, prophylaxis and therapeusis of viral hepatitis B, with focus on reduction to practical applications

被引:62
作者
Hilleman, MR [1 ]
机构
[1] Merck Inst, West Point, PA 19486 USA
关键词
chemotherapeutic; cirrhosis; hepatitis B virus; hepatocarcinoma; T cells;
D O I
10.1016/S0264-410X(00)00364-9
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Hepatitis B is the most important of several hepatitis viruses of man because of the number of cases of the disease and the frequent occurrence of persistent infection that may lead to cirrhosis and cancer of the liver. The pathology of hepatitis B infection results mainly from the self-destructive cytotoxic T cell response of the host. This may be modulated by soluble pre-core c antigen of the virus that induces immune tolerance and by cytokines elaborated by cytotoxic T cells, which suppress viral replication in the infected cell. Pathogenesis of the disease is markedly influenced by viral mutations. Persistent hepatitis B virus infection may be controlled in a minority of patients by passive alpha -interferon therapy, and in a majority of patients by the nucleoside lamivudine until resistance develops. The best means to control the disease is by prevention through application of the highly effective vaccine prepared using surface antigen of the virus. It is anticipated that the gradually increasing application of the vaccine throughout the world may lead to elimination of hepatitis B as an important medical problem. This paper is intended to provide a cursory overview of the contemporary knowledge relating to pathogenesis, prophylaxis and therapeusis of human hepatitis B. (C) 2001 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:1837 / 1848
页数:12
相关论文
共 84 条
[1]  
Andrisani OM, 1999, INT J ONCOL, V15, P373
[2]  
[Anonymous], 1993, Lancet, V342, P63
[3]  
[Anonymous], DIS CONTROL PRIORITI
[4]  
Atkinson W-WC, 2000, EPIDEMIOLOGY PREVENT
[5]  
Banatvala J, 2000, LANCET, V355, P561, DOI 10.1016/S0140-6736(99)07239-6
[6]   Hepatitis viruses: genetic variants and clinical significance [J].
Blum, HE .
INTERNATIONAL JOURNAL OF CLINICAL & LABORATORY RESEARCH, 1997, 27 (04) :213-224
[7]   A SERUM ANTIGEN (AUSTRALIA ANTIGEN) IN DOWNS SYNDROME LEUKEMIA AND HEPATITIS [J].
BLUMBERG, BS ;
GERSTLEY, BJ ;
HUNGERFO.DA ;
LONDON, WT ;
SUTNICK, AI .
ANNALS OF INTERNAL MEDICINE, 1967, 66 (05) :924-+
[8]   Recombination between sequences of hepatitis B virus from different genotypes [J].
Bollyky, PL ;
Rambaut, A ;
Harvey, PH ;
Holmes, EC .
JOURNAL OF MOLECULAR EVOLUTION, 1996, 42 (02) :97-102
[9]  
Bonis PAL, 1999, J AM SOC NEPHROL, V10, P1828
[10]   Relationships within and between genotypes of hepatitis B virus at points across the genome: footprints of recombination in certain isolates [J].
Bowyer, SM ;
Sim, JGM .
JOURNAL OF GENERAL VIROLOGY, 2000, 81 :379-392